Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 3
2003 3
2006 2
2007 1
2008 2
2010 3
2011 4
2012 4
2013 3
2014 2
2015 2
2016 5
2017 1
2018 2
2019 3
2020 1
2021 3
2022 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

45 results

Results by year

Filters applied: . Clear all
Page 1
Activating STING1-dependent immune signaling in TP53 mutant and wild-type acute myeloid leukemia.
Kogan AA, Topper MJ, Dellomo AJ, Stojanovic L, McLaughlin LJ, Creed TM, Eberly CL, Kingsbury TJ, Baer MR, Kessler MD, Baylin SB, Rassool FV. Kogan AA, et al. Among authors: rassool fv. Proc Natl Acad Sci U S A. 2022 Jul 5;119(27):e2123227119. doi: 10.1073/pnas.2123227119. Epub 2022 Jun 27. Proc Natl Acad Sci U S A. 2022. PMID: 35759659 Free PMC article.
Phase I Clinical Trial of DNA Methyltransferase Inhibitor Decitabine and PARP Inhibitor Talazoparib Combination Therapy in Relapsed/Refractory Acute Myeloid Leukemia.
Baer MR, Kogan AA, Bentzen SM, Mi T, Lapidus RG, Duong VH, Emadi A, Niyongere S, O'Connell CL, Youngblood BA, Baylin SB, Rassool FV. Baer MR, et al. Among authors: rassool fv. Clin Cancer Res. 2022 Apr 1;28(7):1313-1322. doi: 10.1158/1078-0432.CCR-21-3729. Clin Cancer Res. 2022. PMID: 35091444 Free PMC article. Clinical Trial.
Pim kinase inhibitor co-treatment decreases alternative non-homologous end-joining DNA repair and genomic instability induced by topoisomerase 2 inhibitors in cells with FLT3 internal tandem duplication.
Scarpa M, Kapoor S, Tvedte ES, Doshi KA, Zou YS, Singh P, Lee JK, Chatterjee A, Ali MKM, Bromley RE, Hotopp JCD, Rassool FV, Baer MR. Scarpa M, et al. Among authors: rassool fv. Oncotarget. 2021 Aug 31;12(18):1763-1779. doi: 10.18632/oncotarget.28042. eCollection 2021 Aug 31. Oncotarget. 2021. PMID: 34504649 Free PMC article.
DNA methyltransferase inhibitors induce a BRCAness phenotype that sensitizes NSCLC to PARP inhibitor and ionizing radiation.
Abbotts R, Topper MJ, Biondi C, Fontaine D, Goswami R, Stojanovic L, Choi EY, McLaughlin L, Kogan AA, Xia L, Lapidus R, Mahmood J, Baylin SB, Rassool FV. Abbotts R, et al. Among authors: rassool fv. Proc Natl Acad Sci U S A. 2019 Nov 5;116(45):22609-22618. doi: 10.1073/pnas.1903765116. Epub 2019 Oct 7. Proc Natl Acad Sci U S A. 2019. PMID: 31591209 Free PMC article.
45 results